(Reuters) - Graham, in slides prepared for his remarks to an advisory
panel, said Avandia increases the risk of cardiovascular
problems such as heart attacks while rival drug Actos, made by
Takeda Pharmaceutical Co. Ltd. , does not.
Senior FDA officials say they do not know if Avandia, known
generically as rosiglitazone, increases heart-attack risk and
are asking the advisory panel if the drug should come off the
market or stay with stronger warnings or limits. Panel
recommendations are expected on Monday afternoon.
Read more at Reuters.com Government Filings News
panel, said Avandia increases the risk of cardiovascular
problems such as heart attacks while rival drug Actos, made by
Takeda Pharmaceutical Co. Ltd. , does not.
Senior FDA officials say they do not know if Avandia, known
generically as rosiglitazone, increases heart-attack risk and
are asking the advisory panel if the drug should come off the
market or stay with stronger warnings or limits. Panel
recommendations are expected on Monday afternoon.
Read more at Reuters.com Government Filings News
No comments:
Post a Comment